- Home
- KNOP vs NGEN Comparison
KNOP vs NGEN Comparison
Compare KNOP & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNOP | NGEN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.5M | 317.6M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNOP | NGEN |
|---|---|---|
| Price | $10.20 | $4.20 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 116.7K | ★ 150.8K |
| Earning Date | 03-18-2026 | 04-02-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | N/A |
| Revenue This Year | $16.11 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.29 | $1.50 |
| 52 Week High | $11.15 | $6.30 |
Technical Indicators
Market Signals| Indicator | KNOP | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 33.39 |
| Support Level | $10.21 | $3.89 |
| Resistance Level | $10.42 | $4.30 |
| Average True Range (ATR) | 0.25 | 0.31 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 1.10 | 54.02 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.